Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 11/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711272 | 0.81 | HSD11B1 (0.50) | HSD11B1SPRDDB1CRBNUSP30 | |
| SCHEMBL23795137 | 0.81 | HSD11B1 (0.50) | HSD11B1SPRDDB1CRBNUSP30 | |
| SCHEMBL18701798 | 0.80 | HSD11B1 (0.49) | HSD11B1SPRDDB1CRBNUSP30 | |
| SCHEMBL31257565 | 0.79 | HSD11B1 (0.42) | HSD11B1TGM2 | |
| SCHEMBL14820383 | 0.77 | HSD11B1 (0.49) | HSD11B1SPRDDB1CRBNUSP30 | |
| SCHEMBL23537913 | 0.77 | KRAS (0.43) | KRASJAK3 | |
| SCHEMBL14805846 | 0.76 | HSD11B1 (0.45) | HSD11B1SPRDDB1CRBNUSP30 | |
| SCHEMBL20326222 | 0.75 | JAK3 (0.44) | KRASJAK3 | |
| SCHEMBL14230805 | 0.74 | HSD11B1 (0.50) | HSD11B1SPRDDB1CRBNUSP30 | |
| SCHEMBL18484521 | 0.73 | HSD11B1 (0.43) | HSD11B1SPRDDB1CRBNUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | HSD11B1 1729/4885KRAS 94/4885SPR 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.